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http://dx.doi.org/10.1016/j.chembiol.2012.07.003Analyzing DNA from tissue has revealed
abundant variation in the human genome.
Thus far, though, the genomes se-
quenced have been analyzed by extract-
ing DNA from tissue that contains
millions of cells analyzed in the same
batch. No two cells are alike; even cells
of the same type may be undergoing
changes in growth that make each cell
genetically different from its siblings.
Sequencing the genome of single cells,
however, can help answer basic ques-
tions such as how the genome evolved
and give researchers an idea of the
heterogeneity found in a tumor, work
that may one day help researchers under-‘‘The best way to begin studying populations of cancer cells is to
look at what happens in single cells’’ — Timour Baslanstand the biology of individual cancer
cells well enough to figure out how some
groups of cancer cells are able to resist
treatment.
At Biology of Genomes, held at Cold
Spring Harbor, New York, on May 812,
2012, four groups of scientists presented
data that offered a glimpse of the poten-
tial of single-cell genomics.
Although it’s too early to say what
the genetic changes detected in single
cells could mean, recent work in breast
cancer found mutations that had not
been shown with batch sequencing and
uncovered diversity in groups of cells
thought to be genetically homogenous.
In cancer, for example, ‘‘bulk sequenc-
ing may be missing mutations that occur
in minor populations in the tumor,’’ says
Nicholas Navin, Ph.D., a geneticist at the
University of Texas MD Anderson Cancer
Center. ‘‘When you think about how
cancer cells respond to chemotherapy
and think about minor populations that
might metastasize, those can be very
important.’’Finding New Hot Spots
Geneticist Adam Auton, Ph.D., of the
Albert Einstein College of Medicine,
Bronx, New York, is looking at individual
sperm cells to study the evolution of the
human genome. Auton is investigating
a gene called PRDM9, which codes for a
protein that localizes at recombination
hot spots, local areas of the genome
where genetic material tends to be ex-
changed between chromosome copies.
PRDM9helps initiate the double-stranded
DNA breaks necessary for cell division,
ensuring that genes recombine in such
a way to allow for genetic diversity to be
maintained.Unlike some model organisms, people
don’t have enough offspring to make the
study of recombination events feasible.
‘‘Unfortunately, identifying human families
where the number of children tends to ’n’
is something of a challenge,’’ Auton says.
Thus, sperm cells give Auton access to
hundreds of gametes in order to identify
recombination events.
Such hot spots can vary between indi-
viduals in ‘‘quite a dramatic fashion,’’
says Auton. Over the long term, Auton
wants to study recombination in multiple
people in order to quantify their variation
and compare recombination rates among
individuals to get a better understanding
of how the genome evolved.
In work presented at Cold Spring
Harbor, Auton searched for recombina-
tion events in the DNA of 167 sperm
cells from a 50-year-old Asian man. Using
this data, he was able to estimate the
recombination rates in this individual,
which he compared to population esti-
mates from the DECODE consortium
(roughly 15,000 individuals) and foundChemistry & Biology 19, July 27, 2012places inwhich the rates of recombination
differed.
Single File
Mutations uncovered thus far in batch
sequencing of the human genome have
come from comparing mutations in
tumors tomutations in normal cells, which
gives a general look at normal cells and at
tumor cells once cancer is established.
‘‘We want to measure the steps along
the way,’’ says Stephen Quake, Ph.D.,
a bioengineer at Stanford University
and cofounder of Fludigm (http://www.
fluidigm.com/) based in San Francisco,
California, which markets a technology
that tells scientists which genes are
switched on and off at a certain moment
in time. Such work is possible because
the system miniaturizes reactions that
once took place on a lab bench and which
can now be analyzed on a chip the size of
a bottle cap. Fluidigm and the Broad Insti-
tute of Harvard and MIT in Cambridge,
Massachusetts, recently launched the
Genomic Single-Cell Center headquar-
tered at the Broad Institute and devoted
to single cell studies in mammalian cells.
‘‘One unifying principle that all cancers
have is evolution, so to understand cancer
you need to understand evolution. The
way you study evolution is to study popu-
lations and that’s what cancer cells are.
The best way to begin studying popula-
tions of cancer cells is to look at what
happens in single cells,’’ says Timour
Baslan, a graduate student from Cold
Spring Harbor Laboratory (CSHL).
James Hicks, Ph.D., a geneticist at
CSHL, sees three ways in which studying
single cells can contribute to cancer
biology. Studying single cancer cells
may be the only way to figure out the full
landscape of the mutations that occur in
cancer genomes or to identify rare cancer
cells that may be circulating in the blood-
stream. Single cell technology also may
be able to help test certain hypotheses
such as whether individual cancer cellsª2012 Elsevier Ltd All rights reserved 785
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the bloodstream only to return, perhaps
years later, and fuel the tumor, a hypoth-
esis known as ‘‘tumor self-seeding,’’
which was developed by Dr. Larry Norton
of Memorial Sloan Kettering Cancer
Center (MSKCC).
CSHL’s Hicks and Baslan have devel-
oped tools to profile individual nuclei
for a myriad of genetic alterations found
in cancer genomes (they are making
this technology available to single-cell
researchers.). Recently, as part of an
ongoing clinical trial with Dr. Lyndsay
Harris, the team scanned hundreds of
individual cells from tumors of different
subtypes in breast cancer, profiling cells
before and after treatment. Data pre-
sented at the meeting found that each
person’s cancer was unique and that
each person responded to the treatment
idiosyncratically. In some patients, a
biopsy of the tumor taken two weeks after
treatment showed that cancer cells
gained genetic material. In other patients,
no genetic material was gained; instead,
what they observed was a rearrangement
in the clonal population percentages of
cancer cells.
‘‘This type of evaluation has been over-
looked in cancer studies,’’ says Baslan.
CSHL’s Hicks plans to refine this tech-
nology in a manner suitable for clinical
testing; for example, to detect genetic
changes in circulating cancer cells mean-
ingful enough to aid therapy. Although
researchers don’t know which mutations
allow a cell to break away from the tumor
and live elsewhere, they do know that
cancer cells travel the bloodstream high-
way to get there. The ability to capture
these traveling cells in a blood test sensi-
tive enough to monitor critical changes
taking place in single cells may one day
help physiciansmake treatment decisions
based on blood tests.
The first single-cell work to reconstruct
tumor evolution in cancer cells was
recently published by Nicholas Navin,
Ph.D., of The University of Texas MD
Anderson Cancer Center (Navin et al.,
2011). Here, Navin looked at copy number
profiling and next-generation sequencing
to reconstruct tumor evolution of a com-
plex breast cancer subtype called triple
negative. This cancer is difficult to treat786 Chemistry & Biology 19, July 27, 2012 ª2because cells do not express receptors
for estrogen, progesterone, or those re-
ceptors sensitive to the drug Herceptin.
Since publication of the Nature paper,
Navin developed an approach that can
detect genome-wide point mutations
and indels (a group of mutations where
DNA is either inserted or deleted) base-
pair resolution in addition to copy number.
Because the technique covers 80%
90% of the genome of a single cell, Navin
says he can use fewer cells to resolve the
clonal diversity of a tumor. His method
also minimizes the amount that DNA has
to be amplified, thus introducing lower
percentage of false positives.
Navin used this technique on a breast
cancer cell line (SK-BR-3) thought to
be homogenous; he found that the
majority of mutations were similar in 99
percent of the genome. In about 1% of
the genome, though, the team observed
diversity between mutations in two single
cells. One percent represents about
12,000 or 20,000 mutations across the
genome, says Navin.
Next, the team studied a type of breast
cancer called ER+, which is considered
a homogenous tumor. This subtype is
classified by cells that either respond
or do not respond to estrogen. Navin
found between 20 and 30 new muta-
tions in genes in each single cell. These
somatic mutations could not have
been identified by the bulk sequencing
methods currently used to distinguish
cancer cells from normal cells. Such
methods detect high frequency mutations
(more important for driving the cancer)
but might miss rare cells in minor sub-
populations. Many of these mutations
occurred in places likely to disrupt protein
function, says Navin, suggesting that they
may have phenotypic effects on the indi-
vidual cells.
So far Navin’s latest effort looked at just
one tumor, so more basic research will
need to be done to assess the extent of
clonal diversity and to compare mutations
in single-cell populations to genomic data
from similar types of breast cancers.
One aspect that may be lacking in
single-cell genomics is sensitivity. The
resolution in single-cell technologies is
less than the batch method (taking a tiny
chunk of tumor that includes many cells012 Elsevier Ltd All rights reservedand then identifying mutations), says
Elaine Mardis, Ph.D., codirector of The
Genome Institute at Washington Univer-
sity in St. Louis in St. Louis, Missouri.
The team of researchers at the Genome
Institute has been using the batchmethod
to studymany types of cancer. Even using
the batch method, however, requires
going back to the original sample for
further tests to have confidence in the
results, says Mardis. With single cells,
there may not be enough original material
for further validation.
‘‘For now, methods that sequence DNA
isolated from the bulk tumor are yielding
important insights into tumor heteroge-
neity. ‘‘Single-cell sequencing is an ex-
citing technical challenge, but how many
cells do you need to sequence before
you sort out how many different sub-
clones you have,’’ says Mardis.
Such work doesn’t require a large
number of cells because representative
cells can be studied, says Navin. Navin
compares single-cell data in a manner
similar to the way pollsters appraise polit-
ical opinion or zoologists count members
of new species in the rainforest. Pollsters
and zoologists don’t have to assess every
individual: they extrapolate to a larger
group using statistical assessments and
random sampling. Likewise, scientists
collecting genetic data from single cells
can estimate population diversity by
studying select cells.
With such answers in hand, single cell
technologies may one day reach the clinic
to test whether cancer will resist chemo-
therapy.‘‘I think that one day, single cell
technologies could be very powerful in
detecting residual disease after treatment
with chemotherapy or in identifying which
patients might have circulating tumor
cells,’’ says Navin. ‘‘I hope that these tools
can be used to improve the diagnosis of
patients and improve treatment.’’REFERENCE
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